Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation. (31st March 2015)

• Record Type: Journal Article
• Authors: Nygaard, M.; Hovgaard, D.; Schjødt, I. M.; Andersen, N. S.; Vindeløv, L.; Sengeløv, H.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 40:Number 3(2015:Jun.)
• Page Start: 358
• Page End: 361
• Publication Date: 2015-03-31
• Subjects: cost‐effectiveness -- cyclosporine -- intravenous infusions -- oral administration -- therapeutic drug monitoring; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12266
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: The target level and route of administration of cyclosporine A (CsA) differ between transplantation centres. It is unclear whether oral CsA is sufficient to maintain target level of CsA. Case summary: We retrospectively analysed data from 48 adult patients, who underwent myeloablative hematopoietic stem cell transplantation. Twenty‐one patients (44%) tolerated CsA orally throughout the transplantation period without increased incidence of acute graft versus host disease(aGVHD). Low concentration of CsA in week 2 was associated with increased incidence of aGVHD. What is new and conclusion: Oral administration of CsA is safe, less time‐consuming and economically advantageous. Close monitoring of CsA concentration is important. Abstract : Maintaining concentration of cyclosporine A within target level in the early post‐transplant period is important to prevent acute graft versus host disease. In 48 consecutive patients undergoing myeloablative hematopoietic stem cell transplantation, we show that oral administration of cyclosporine A is feasible and efficient in preventing acute graft versus host disease. Oral administration during the entire transplant period was possible in 21 of 48 patients.